- Report
- March 2025
- 149 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2024
- 128 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- February 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- October 2021
- 395 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- August 2022
Global
From €1036EUR$1,090USD£871GBP
- Drug Pipelines
- July 2020
- 440 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- November 2022
- 71 Pages
Global
From €1901EUR$2,000USD£1,597GBP
The Brain Injury Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. These drugs are used to treat a variety of conditions, including traumatic brain injury, stroke, Alzheimer's disease, Parkinson's disease, and epilepsy. Brain Injury Drugs are designed to reduce the severity of brain injury and improve the patient's quality of life. They can also be used to reduce the risk of further injury and improve cognitive function. Commonly used drugs in this market include anticonvulsants, anti-inflammatory drugs, and neuroprotective agents.
Some companies in the Brain Injury Drug market include AbbVie, AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more
